The phase III SOLO-1 trial demonstrated a long-term progression-free survival benefit of Lynparza versus placebo as a first-line maintenance treatment in patients with newly diagnosed, advanced BRCA-mutated ovarian cancer who were in complete or partial response to platinum-based chemotherapy.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
